Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's issuing a voluntary medical device correction for some of its FreeStyle ...

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of hundreds of injuries and seven deaths worldwide—after some sensors showed they ...

As it embarks on a widespread effort to remind users of the proper care and keeping of the hand-held readers used with its FreeStyle Libre continuous glucose monitors, Abbott is further expanding the ...

Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that a number of them may be ...

Patients are being warned to stop using some glucose monitors made by Abbott Diabetes Care after the company found malfunctioning sensors may be linked to hundreds of adverse events and several deaths ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...

Malfunctioning glucose trackers made by Abbott Diabetes Care have been linked to more than 700 severe adverse events and seven potential deaths, the Food and Drug Administration (FDA) and Abbott said.